Johnson & Johnson (JNJ) - Pharmaceutical Revenue (DISCONTINUED) (I:JJJNJPR)
52.56B USD for 2023
Level Chart
Basic Info
|
Johnson & Johnson (JNJ) - Pharmaceutical Revenue is at a current level of 52.56B, up from 45.57B one year ago. This is a change of 15.34% from one year ago. |
|
Pharmaceutical Revenue refers to the total revenue generated by Johnson & Johnson from its pharmaceutical segment. |
| Report | FinChat.io |
| Category | Segments & KPIs |
| Region | United States |
| Source | FinChat.io |
|
Data provided via FinChat.io |
Stats
| Last Value | 52.56B |
| Latest Period | 2023 |
| Last Updated | Jan 12 2024, 16:52 EST |
| Average Growth Rate | 7.70% |
| Value from 1 Year Ago | 45.57B |
| Change from 1 Year Ago | 15.34% |
| Frequency | Yearly |
| Unit | USD |
| Adjustment | N/A |
Historical Data
| Date | Value |
|---|---|
| January 01, 2023 | 52.56B |
| January 02, 2022 | 51.68B |
| January 03, 2021 | 45.57B |
| December 29, 2019 | 42.20B |
| December 30, 2018 | 40.73B |
| December 31, 2017 | 36.26B |
| Date | Value |
|---|---|
| January 01, 2017 | 33.46B |
| January 03, 2016 | 31.43B |
| December 28, 2014 | 32.31B |
| December 29, 2013 | 28.12B |
| December 30, 2012 | 25.35B |
News
Headline
Wire
Time (ET)
Accesswire
11/15 12:05
PR Newswire
11/12 08:00
PR Newswire
11/05 05:00
PR Newswire
10/31 07:30
PR Newswire
10/30 06:30
PR Newswire
10/30 06:11
Basic Info
|
Johnson & Johnson (JNJ) - Pharmaceutical Revenue is at a current level of 52.56B, up from 45.57B one year ago. This is a change of 15.34% from one year ago. |
|
Pharmaceutical Revenue refers to the total revenue generated by Johnson & Johnson from its pharmaceutical segment. |
| Report | FinChat.io |
| Category | Segments & KPIs |
| Region | United States |
| Source | FinChat.io |
|
Data provided via FinChat.io |
Stats
| Last Value | 52.56B |
| Latest Period | 2023 |
| Last Updated | Jan 12 2024, 16:52 EST |
| Average Growth Rate | 7.70% |
| Value from 1 Year Ago | 45.57B |
| Change from 1 Year Ago | 15.34% |
| Frequency | Yearly |
| Unit | USD |
| Adjustment | N/A |